Eli Lilly and (LLY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Eli Lilly and

NYSE•Healthcare•Drug Manufacturers - General

$1,154.24+1.80(<0.01%)Market open

Market Cap

$1.03T

P/E

38.5x

P/S

12.9x

P/B

30.4x

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

How this company scores

GoodMetricSide Score: 76/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability22/25

Growth25/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality15/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 38.5x5y range 31.4x – 111.6x

Currently below its 20-quarter median.

P/S · 12.9x5y range 7.5x – 21.0x

Currently near its 20-quarter median.

P/B · 30.4x5y range 25.4x – 59.8x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.2x) — earnings may be inflated by non-cash items or aggressive accounting.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $1.03T

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $79.67B
Q. Revenue: $22.97B
TTM EBITDA: $35.73B
TTM Op. Income: $33.63B
Q. Op. Income: $8.98B
TTM Net Income: $26.71B
Q. Net Income: $7.09B
EPS: N/A
Shares Out.: $892.40M

$79.67B in TTM revenue grew 49.6% YoY, reaching $22.97B last quarter. TTM EBITDA of $35.73B and TTM operating income of $33.63B show growth is flowing through to the bottom line. TTM net income of $26.71B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 41.4%
Op. Margin: 39.1%
Net Margin: 30.9%

Op. margin of 39.1% is down 5.1% YoY — costs are rising relative to revenue. Net margin at 30.9% Over the past year, operating margin is down 11% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 38.5x
P/S Ratio: 12.9x
P/B Ratio: 30.4x

At 38.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 12.9x and P/B of 30.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 24% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $142.28B
Cash: $8.95B
Long-Term Debt: $47.86B
Book Value: $33.88B
D/E Ratio: 1.4
Debt/EBITDA: 5.0

With $142.28B in assets and $47.86B in long-term debt, D/E is 1.4and book value is $33.88B — moderate leverage. Over the past year, debt/equity is down 24% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $10.69B
TTM Free Cash Flow: $13.56B
FCF Margin: 17.0%
FCF / Net Income: 0.5

TTM FCF of $13.56B on $10.69B in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.